Arena Pharmaceuticals Inc

Arena Pharmaceuticals — Technical Presentation (March 2018)

23 slides from Arena Pharmaceuticals's technical presentation, Mar 19, 2018

  1. Slide 1: Etrasimod Phase 2 in Ulcerative Colitis OASIS Clinical Trial Results

    March 19, 2017 Etrasimod Phase 2 in Ulcerative Colitis OASIS Clinical Trial Results Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about our investigative stage drug candidate etrasimod, including its potential to become best-in-class, profile, and phase 3 program and other deve

  3. Slide 3: Etrasimod Phase 2 in Ulcerative Colitis OASIS Clinical Trial Results

    March 19, 2017 Etrasimod Phase 2 in Ulcerative Colitis OASIS Clinical Trial Results

  4. Slide 4: Etrasimod Phase 2 Trial in Ulcerative Colitis (OASIS)

    Etrasimod Phase 2 Trial in Ulcerative Colitis (OASIS) Week 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study 12-Week Induction Phase Exit/Transition to Extension Study 12-Week Treatment Period 1 mg q.d. etrasimod 2 mg q.d. etrasimod P

  5. Slide 5: Endpoints Reported Today

    Endpoints Reported Today Primary Endpoint: Change in 3-component Mayo Clinic Score (score ranging from 0 to 9; stool frequency, rectal bleeding, and findings on endoscopy) at Week 12 Secondary Endpoints: Proportion of patients who achieve endoscopic improvement at Week 12 Change in 2-component Mayo

  6. Slide 6: Statistical Analysis Plan

    Statistical Analysis Plan ANCOVA* model used to estimate changes in Mayo Clinic Score Mantel-Haenszel method** used to estimate proportion difference for dichotomous parameters Missing individual Mayo Clinic subscores impacting efficacy measures were imputed using multiple imputation methodology Obs

  7. Slide 7: Patient Disposition

    Patient Disposition Placebo Etrasimod 1 mg Etrasimod 2 mg Received Study Treatment, N 54 52 50 Completed Study, n (%) 48 (88.9) 47 (90.4) 46 (92.0) Early Discontinuation, n (%) 6 (11.1) 5 (9.6) 4 (8.0)

  8. Slide 8: Baseline Characteristics

    Baseline Characteristics Placebo (N=54) Etrasimod 1 mg (N=52) Etrasimod 2 mg (N=50) Mean Age, Years 44.8 43.2 40.4 Sex, n (%) Male 32 (59.3) 30 (57.7) 27 (54.0) Female 22 (40.7) 22 (42.3) 23 (46.0) Race, n (%) White 51 (94.4) 48 (92.3) 49 (98.0) Non-White 3 (5.6) 4 (7.7) 1 (2.0) Mean Weight, kg 75.7

  9. Slide 9: Overall Safety & Tolerability

    Overall Safety & Tolerability Placebo (N=54) Etrasimod 1 mg (N=52) Etrasimod 2 mg (N=50) Number (%) of Patients with any TEAE 27 (50.0) 31 (59.6) 28 (56.0) Number (%) of Patients with TEAE Leading to Discontinuation of Study Drug 0 3 (5.8) 4 (8.0) Number (%) of Patients with Serious TEAE 6 (11.1) 3

  10. Slide 10: Cardiac Safety Summary

    Cardiac Safety Summary Impact on HR and AV conduction was low throughout the study with no discontinuations related to bradycardia or AV block No SAEs related to HR changes or AV block were recorded Hourly ECGs on Day 1 demonstrated no mean changes in HR ≥ 10 bpm in either etrasimod group at any tim

  11. Slide 11: Adverse Events of Special Interest

    Adverse Events of Special Interest No increases in liver function tests compared to placebo No reports of macular edema No reports of abnormal pulmonary function tests

  12. Slide 12: Primary Endpoint: 3-Component Mayo Clinic Score

    Primary Endpoint: 3-Component Mayo Clinic Score Change on 9-Point Scale Including Rectal Bleeding, Stool Frequency, Endoscopy LS=least square; Δ LS mean difference from placebo. LS mean was estimated using an ANCOVA model that includes current oral corticosteroid therapy at baseline and previous exp

  13. Slide 13: Secondary Endpoint: Endoscopic Improvement

    Secondary Endpoint: Endoscopic Improvement Proportion of Patients with Mayo Clinic Subscore of 0 or 1 points Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists. Δ = 4.1% (p = 0.306) Δ = 24.4% (p = 0.

  14. Slide 14: Secondary Endpoints: 2-Component Mayo Clinic Score & Total Mayo Clinic Score

    Secondary Endpoints: 2-Component Mayo Clinic Score & Total Mayo Clinic Score 2-Component Mayo Clinic Score: Change on 6-point Scale (Rectal Bleeding, Endoscopy). Total Mayo Clinic Score: Change on 12-point scale (Rectal Bleeding, Stool Frequency, Endoscopy, PGA). LS=least square; Δ LS mean differenc

  15. Slide 15: Lymphocyte Reduction

    Lymphocyte Reduction Mixed effects model with current oral corticosteroid use, previous exposure to TNFa antagonists, treatment, week and treatment-by-week interaction, as factors and baseline value as covariate. All values p < 0.001

  16. Slide 16: Clinical Remission (3-Component)

    Clinical Remission (3-Component) Proportion of Patients with Endoscopy, Rectal Bleeding and Stool Frequency Mayo Clinic Subscore of ≤ 1 point and Stool Frequency Improvement of ≥ 1 point Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use

  17. Slide 17: Clinical Remission (Total MCS)

    Clinical Remission (Total MCS) Proportion of Patients with Total Mayo Clinic Score ≤ 2 points and No Subscore > 1 point MCS = Mayo Clinic Score Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TN

  18. Slide 18: Endoscopic Improvement in UC Studies of S1P Modulators

    Endoscopic Improvement in UC Studies of S1P Modulators Proportion of Patients with Mayo Clinic Subscore of 0 or 1 points Etrasimod: Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists. Ozanimod: Sandb

  19. Slide 19: Endoscopic Improvement in UC Studies

    Endoscopic Improvement in UC Studies Proportion of Patients with Mayo Clinic Subscore of 0 or 1 points Etrasimod: Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use, prior exposure to TNFα antagonists. Sources: Ozanimod: Sandborn, et al.

  20. Slide 20: Clinical Remission (Total MCS) in UC Studies of S1P Modulators

    Clinical Remission (Total MCS) in UC Studies of S1P Modulators Proportion of Patients with Total Mayo Clinic Score ≤ 2 points and No Subscore > 1 point Total MCS = Mayo Clinic Score Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current

  21. Slide 21: Clinical Remission (Total Mayo Clinic Score) in UC Studies

    Clinical Remission (Total Mayo Clinic Score) in UC Studies Proportion of Patients with Total Mayo Clinic Score ≤ 2 points and No Subscore > 1 point Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior

  22. Slide 22: Etrasimod 2 mg Demonstrated Statistically Significant Improvements in Multiple Clinical Endpoints

    Etrasimod 2 mg Demonstrated Statistically Significant Improvements in Multiple Clinical Endpoints MCS = Mayo Clinic Score. Placebo adjusted mean changes from baseline in endpoints. Statistical testing for each clinical endpoint utilized single sided testing, with significance set at p < 0.025. Endos

  23. Slide 23: Etrasimod Phase 2 Results Reflect a Strong Development Program and Paves Way for Phase 3

    Etrasimod Phase 2 Results Reflect a Strong Development Program and Paves Way for Phase 3 We believe etrasimod has: Best S1P receptor selectivity and pharmacodynamics in the class Phase 2 data supporting best-in-class potential Clinical utility across multiple immune and inflammatory conditions Favor

Arena Pharmaceuticals — Technical Presentation (March 2018) on 6ix